{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:20:53Z","timestamp":1790778053335,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T00:00:00Z","timestamp":1518480000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"ArmaGen, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40259-018-0264-7","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T10:31:50Z","timestamp":1518517910000},"page":"169-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-1338","authenticated-orcid":false,"given":"William M.","family":"Pardridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben J.","family":"Boado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,13]]},"reference":[{"key":"264_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev.bi.60.070191.001353","volume":"60","author":"EF Neufeld","year":"1991","unstructured":"Neufeld EF. Lysosomal storage diseases. Annu Rev Biochem. 1991;60:257\u201380.","journal-title":"Annu Rev Biochem."},{"issue":"5","key":"264_CR2","first-page":"381","volume":"7","author":"JJ Hopwood","year":"1990","unstructured":"Hopwood JJ, Morris CP. The mucopolysaccharidoses. Diagnosis, molecular genetics and treatment. Mol Biol Med. 1990;7(5):381\u2013404.","journal-title":"Mol Biol Med."},{"issue":"3","key":"264_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344(3):182\u20138.","journal-title":"N Engl J Med."},{"issue":"5","key":"264_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144(5):581\u20138.","journal-title":"J Pediatr."},{"issue":"4","key":"264_CR5","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1021\/acs.molpharmaceut.6b01166","volume":"14","author":"RJ Boado","year":"2017","unstructured":"Boado RJ, Pardridge WM. Brain and organ uptake in the rhesus monkey in vivo of recombinant iduronidase compared to an insulin receptor antibody-iduronidase fusion protein. Mol Pharm. 2017;14(4):1271\u20137.","journal-title":"Mol Pharm."},{"issue":"13","key":"264_CR6","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","volume":"125","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, Wynn RF, Orchard PJ, O\u2019Meara A, Veys P, Fischer A, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125(13):2164\u201372.","journal-title":"Blood."},{"issue":"4","key":"264_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/cpt.18","volume":"97","author":"WM Pardridge","year":"2015","unstructured":"Pardridge WM. Targeted delivery of protein and gene medicines through the blood-brain barrier. Clin Pharmacol Ther. 2015;97(4):347\u201361.","journal-title":"Clin Pharmacol Ther."},{"issue":"2","key":"264_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jbiotec.2009.08.019","volume":"144","author":"RJ Boado","year":"2009","unstructured":"Boado RJ, Hui EK, Lu JZ, Pardridge WM. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol. 2009;144(2):135\u201341.","journal-title":"J Biotechnol."},{"key":"264_CR9","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1073\/pnas.86.14.5217","volume":"86","author":"MA Soos","year":"1989","unstructured":"Soos MA, O\u2019Brien RM, Brindle NP, Stigter JM, Okamoto AK, Whittaker J, et al. Monoclonal antibodies to the insulin receptor mimic metabolic effects of insulin but do not stimulate receptor autophosphorylation in transfected NIH 3T3 cells. Proc Natl Acad Sci USA. 1989;86:5217\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"264_CR10","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1111\/j.1471-4159.1985.tb07167.x","volume":"44","author":"WM Pardridge","year":"1985","unstructured":"Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier insulin receptor. J Neurochem. 1985;44(6):1771\u20138.","journal-title":"J Neurochem."},{"key":"264_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1023\/A:1016244500596","volume":"12","author":"WM Pardridge","year":"1995","unstructured":"Pardridge WM, Kang YS, Buciak JL, Yang Y. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res. 1995;12:807\u201316.","journal-title":"Pharm Res."},{"issue":"10","key":"264_CR12","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1124\/dmd.112.046375","volume":"40","author":"RJ Boado","year":"2012","unstructured":"Boado RJ, Hui EK, Lu JZ, Pardridge WM. Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metab Dispos. 2012;40(10):2021\u20135.","journal-title":"Drug Metab Dispos."},{"issue":"1","key":"264_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1021\/bc3005123","volume":"24","author":"RJ Boado","year":"2013","unstructured":"Boado RJ, Hui EK, Lu JZ, Pardridge WM. IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys. Bioconjug Chem. 2013;24(1):97\u2013104.","journal-title":"Bioconjug Chem."},{"issue":"3","key":"264_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1006\/prep.1994.1035","volume":"5","author":"ED Kakkis","year":"1994","unstructured":"Kakkis ED, Matynia A, Jonas AJ, Neufeld EF. Overexpression of the human lysosomal enzyme alpha-l-iduronidase in Chinese hamster ovary cells. Protein Expr Purif. 1994;5(3):225\u201332.","journal-title":"Protein Expr Purif."},{"issue":"4","key":"264_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ymgme.2016.02.006","volume":"117","author":"Y Xue","year":"2016","unstructured":"Xue Y, Richards SM, Mahmood A, Cox GF. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: a comprehensive meta-analysis of pooled data from multiple studies. Mol Genet Metab. 2016;117(4):419\u201326.","journal-title":"Mol Genet Metab."},{"issue":"1","key":"264_CR16","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-l-iduronidase (laronidase). Pediatrics. 2007;120(1):e37\u201346.","journal-title":"Pediatrics."},{"issue":"9","key":"264_CR17","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1021\/acs.molpharmaceut.6b00456","volume":"13","author":"RJ Boado","year":"2016","unstructured":"Boado RJ, Hui EK, Lu JZ, Pardridge WM. Very high plasma concentrations of a monoclonal antibody against the human insulin receptor are produced by subcutaneous injection in the Rhesus monkey. Mol Pharm. 2016;13(9):3241\u20136.","journal-title":"Mol Pharm."},{"issue":"2","key":"264_CR18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/0006-291X(90)90741-5","volume":"172","author":"M Ballesteros","year":"1990","unstructured":"Ballesteros M, Scott CD, Baxter RC. Developmental regulation of insulin-like growth factor-II\/mannose 6-phosphate receptor mRNA in the rat. Biochem Biophys Res Commun. 1990;172(2):775\u20139.","journal-title":"Biochem Biophys Res Commun."},{"issue":"4","key":"264_CR19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/mrd.1080350415","volume":"35","author":"P Nissley","year":"1993","unstructured":"Nissley P, Kiess W, Sklar M. Developmental expression of the IGF-II\/mannose 6-phosphate receptor. Mol Reprod Dev. 1993;35(4):408\u201313.","journal-title":"Mol Reprod Dev."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-018-0264-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0264-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0264-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T20:42:03Z","timestamp":1550004123000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-018-0264-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,13]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["264"],"URL":"https:\/\/doi.org\/10.1007\/s40259-018-0264-7","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,13]]},"assertion":[{"value":"13 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Drs. Ruben Boado and Mathias Schmidt are employees of, and Drs. William M. Pardridge and Roberto Giugliani are consultants to, ArmaGen, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with Good Clinical Practice, the Declaration of Helsinki, and current guidelines for studies in patients in Brazil, and was approved by the National Ethics Committee (CONEP) in Brazil.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants, or their representatives, gave their written consent prior to the start of any study-related activities.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}